Potent and selective PPARγ agonist (EC50 = 60 nM); exhibits no activity at PPARα and PPARβ. Promotes differentiation of pluripotent C3H10T1/2 stem cells into adipocytes. Exhibits antihyperglycemic activity in diabetic ob/ob mouse model. Antidiabetic agent.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 357.43. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.8 mL||13.99 mL||27.98 mL|
|5 mM||0.56 mL||2.8 mL||5.6 mL|
|10 mM||0.28 mL||1.4 mL||2.8 mL|
|50 mM||0.06 mL||0.28 mL||0.56 mL|
References are publications that support the biological activity of the product.
Lehmann et al (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J.Biol.Chem. 270 12953 PMID: 7768881
Willson et al (1996) The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J.Med.Chem. 39 665 PMID: 8576907
If you know of a relevant reference for Rosiglitazone, please let us know.
View Related Products by Product Action
Keywords: Rosiglitazone, Rosiglitazone supplier, BRL49653, High, affinity, selective, PPAR, agonist, thiazolidinedione, TZD, derivative, antidiabetic, agent, BRL, 49653, PPARgamma, Receptors, Other, Differentiation, Products, 5325, Tocris Bioscience
3 Citations for Rosiglitazone
Citations are publications that use Tocris products. Selected citations for Rosiglitazone include:
Warrick et al (2016) FOXA1, GATA3 and PPARγ Cooperate to Drive Luminal Subtype in Bladder Cancer: A Molecular Analysis of Established Human Cell Lines. Sci Rep 6 38531 PMID: 27924948
Matsa et al (2016) Transcriptome Profiling of Patient-Specific Human iPSC-Cardiomyocytes Predicts Individual Drug Safety and Efficacy Responses In Vitro. Cell Stem Cell. 19 311 PMID: 27545504
Ahlem et al (2011) Studies of the pharmacology of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol, a synthetic anti-inflammatory androstene. Int J Clin Exp Med 4 119 PMID: 21686136
Do you know of a great paper that uses Rosiglitazone from Tocris? Please let us know.
Reviews for Rosiglitazone
There are currently no reviews for this product. Be the first to review Rosiglitazone and earn rewards!
Have you used Rosiglitazone?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.